Palbociclib-d8 manufacturers
- Palbociclib-D8
-
-
2023-05-27
- CAS:1628752-83-9
- Min. Order: 1mg
- Purity: 96%
- Supply Ability: 50mg
|
| | Palbociclib-d8 Basic information |
| Product Name: | Palbociclib-d8 | | Synonyms: | Palbociclib-d8;PD 0332991-d8;[2H8]-Palbociclib;6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl-2,2,3,3,5,5,6,6-d8)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;Palbociclib D8Q: What is
Palbociclib D8 Q: What is the CAS Number of
Palbociclib D8 Q: What is the storage condition of
Palbociclib D8 Q: What are the applications of
Palbociclib D8;6-acetyl-8-cyclopentyl-5-methyl-2-({5-[(2,2,3,3,5,5,6,6-2H?)piperazin-1-yl]pyridin-2-yl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one;*Tramadol Impurity 24;D8-Palbociclib | | CAS: | 1628752-83-9 | | MF: | C24H21D8N7O2 | | MW: | 455.582054224 | | EINECS: | | | Product Categories: | | | Mol File: | 1628752-83-9.mol |  |
| | Palbociclib-d8 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: Soluble | | form | A solid | | color | Light yellow to yellow |
| | Palbociclib-d8 Usage And Synthesis |
| Uses | Palbociclib-d8 is labelled Palbociclib (P139900), an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. | | IC 50 | Cdk4/cyclin D3: 9 nM (IC50); Cdk4/cyclin D1: 11 nM (IC50); Cdk6/cyclin D2: 16 nM (IC50); DYRK1A: 2000 nM (IC50); MAPK: 8000 nM (IC50) |
| | Palbociclib-d8 Preparation Products And Raw materials |
|